TW200616612A - Method for the teatment of polycystic kidney disease field of invention - Google Patents

Method for the teatment of polycystic kidney disease field of invention

Info

Publication number
TW200616612A
TW200616612A TW094133944A TW94133944A TW200616612A TW 200616612 A TW200616612 A TW 200616612A TW 094133944 A TW094133944 A TW 094133944A TW 94133944 A TW94133944 A TW 94133944A TW 200616612 A TW200616612 A TW 200616612A
Authority
TW
Taiwan
Prior art keywords
kidney disease
polycystic kidney
teatment
disease field
inhibitor
Prior art date
Application number
TW094133944A
Other languages
English (en)
Chinese (zh)
Inventor
Philip Frost
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200616612A publication Critical patent/TW200616612A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW094133944A 2004-10-08 2005-09-29 Method for the teatment of polycystic kidney disease field of invention TW200616612A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61698104P 2004-10-08 2004-10-08

Publications (1)

Publication Number Publication Date
TW200616612A true TW200616612A (en) 2006-06-01

Family

ID=36013658

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094133944A TW200616612A (en) 2004-10-08 2005-09-29 Method for the teatment of polycystic kidney disease field of invention

Country Status (12)

Country Link
US (1) US20060079515A1 (enExample)
EP (1) EP1796727A2 (enExample)
JP (1) JP2008515913A (enExample)
CN (1) CN101102757A (enExample)
AR (1) AR052221A1 (enExample)
AU (1) AU2005294258A1 (enExample)
BR (1) BRPI0516533A (enExample)
CA (1) CA2580864A1 (enExample)
MX (1) MX2007004001A (enExample)
PE (1) PE20060681A1 (enExample)
TW (1) TW200616612A (enExample)
WO (1) WO2006042100A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
JP2010523579A (ja) 2007-04-02 2010-07-15 インスティテュート フォア ワンワールド ヘルス Ｃｆｔｒ阻害剤化合物およびそれらの使用
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
CA2730715C (en) 2008-08-04 2013-10-01 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
AU2011293315A1 (en) 2010-08-26 2013-03-14 Symphony Evolution, Inc. Use of a receptor-type kinase modulator for treating polycystic kidney disease
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
WO2003050090A1 (en) * 2001-11-27 2003-06-19 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of egf-r and her2 kinases

Also Published As

Publication number Publication date
AR052221A1 (es) 2007-03-07
WO2006042100A3 (en) 2007-06-07
WO2006042100A2 (en) 2006-04-20
CN101102757A (zh) 2008-01-09
EP1796727A2 (en) 2007-06-20
AU2005294258A1 (en) 2006-04-20
JP2008515913A (ja) 2008-05-15
CA2580864A1 (en) 2006-04-20
PE20060681A1 (es) 2006-08-28
BRPI0516533A (pt) 2008-09-09
MX2007004001A (es) 2007-05-11
US20060079515A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
TW200616612A (en) Method for the teatment of polycystic kidney disease field of invention
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
WO2006105081A3 (en) Pharmacokinetically improved compounds
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2008049123A8 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2007079164A3 (en) Protein kinase inhibitors
WO2007115289A8 (en) Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
WO2007120656A3 (en) Uses and compositions for treatment of rheumatoid arthritis
WO2007139960A3 (en) Compounds that modulate hsp90 activity and methods for identifying same
NO20092609L (no) Tannate salt of rasagiline
WO2004073653A8 (en) Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
ATE554087T1 (de) Neue kinaseinhibitoren
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2008049856A3 (en) Methods of treating pain using cdk inhibitors
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2004017948A8 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2006125616A3 (en) Pyrimidine-based cdk inhibitors for treating pain
WO2006110638A3 (en) Inhibitors of akt activity
WO2008011483A3 (en) Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2007098047A3 (en) Methods and compositions for the treatment of parkinson's disease
WO2004021988A3 (en) Treatment of pain by inhibition of p38 map kinase